BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 11417963)

  • 1. Prognostic and predictive factors in breast cancer.
    Bundred NJ
    Cancer Treat Rev; 2001 Jun; 27(3):137-42. PubMed ID: 11417963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.
    Le Goff JM; Lavayssière L; Rouëssé J; Spyratos F
    Anticancer Res; 2000; 20(3B):2213-8. PubMed ID: 10928180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive factors in early-stage breast cancer.
    Cianfrocca M; Goldstein LJ
    Oncologist; 2004; 9(6):606-16. PubMed ID: 15561805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oestrogen and progesterone receptor determinations in breast cancer: technology and biology.
    Thorpe SM; Rose C
    Cancer Surv; 1986; 5(3):505-25. PubMed ID: 3555780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy.
    Takei H; Horiguchi J; Maemura M; Koibuchi Y; Oyama T; Yokoe T; Iino Y; Morishita Y
    Oncol Rep; 2002; 9(2):375-8. PubMed ID: 11836611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.
    Truong PT; Yong CM; Abnousi F; Lee J; Kader HA; Hayashi A; Olivotto IA
    J Am Coll Surg; 2005 Jun; 200(6):912-21. PubMed ID: 15922205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in primary breast cancer.
    McGuire WL
    Cancer Surv; 1986; 5(3):527-36. PubMed ID: 3555781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oestrogen receptors revisited: long-term follow up of over five thousand breast cancer patients.
    Hähnel R; Spilsbury K
    ANZ J Surg; 2004 Nov; 74(11):957-60. PubMed ID: 15550082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oestrogen-progesterone receptor ratio: an indicator of breast cancer evolution.
    Cherubini M; Baxa P; Guarino G
    Chir Ital; 2002; 54(4):423-8. PubMed ID: 12239750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of prognostic factors and effect on survival in young (< or =40) breast cancer patients: a case-control study.
    Hartley MC; McKinley BP; Rogers EA; Kalbaugh CA; Messich HS; Blackhurst DW; Lokey JS; Trocha SD
    Am Surg; 2006 Dec; 72(12):1189-94; discussion 1194-5. PubMed ID: 17216817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers.
    Masood S
    Surg Oncol Clin N Am; 1995 Oct; 4(4):601-32. PubMed ID: 8535901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.